News

PNH is a debilitating, ultra-rare, life-threatening blood disorder in which uncontrolled activation of complement, a component of the immune system, results in hemolysis (destruction of a patient’s red

The Swiss drugmaker signed a collaboration and option agreement, which is subject to customary closing conditions and regulatory approvals. Ionis developed two investigational antisense therapies, dubbed AKCEA-APO(a)-LRx and

Humira is currently approved in the US, the European Union and other markets for arthritis related problems and other indications. The investigational compound PF-06410293, a monoclonal antibody (mAb), met

SGN-CD352A is an investigational CD352-targeted antibody-drug conjugate (ADC) utilizing Seattle Genetics’ proprietary ADC technology, an engineered cysteine antibody (EC-mAb) stably linked to a highly potent cytotoxic agent called

Under the terms of the development agreement, PvP will conduct all research and development through phase 1 proof-of-principle studies per a pre-defined development plan. Takeda will fund $35

Meeting minutes received from the FDA’s Division of Anti-Infective Products confirmed key elements of the company’s overall plan for benznidazole, including: The company’s proposed 505(b)(2) approach to demonstrate

Microbion, co-located in Vancouver, BC and Bozeman, MT, is a clinical stage biopharmaceutical company specializing in the treatment of hard to treat and antibiotic-resistant infections. Microbion's lead compound,

BMS’ immuno-oncology agent Opdivo will now be assessed with Janssen’s Darzalex in multiple myeloma, as well as several solid tumor types including including non-small cell lung cancer, pancreatic cancer,

HCC is the most common form of liver cancer, a disease that affects nearly 40,000 patients in the United States and is the second deadliest form of cancer